Revenue $13.07B, up 6.9% on a year earlier. Eliquis Worldwide Revenue $4.69B, up 25.2%. Opdivo Worldwide Revenue $2.37B, down 6.2%. Diluted EPS $1.05 against $1.08.
| Q3 FY26 | Q2 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $13.07B | $12.97B | $12.22B | +6.9% |
| Operating income | $2.54B | $4.09B | $3.11B | -18.6% |
| Net income | $2.16B | $3.32B | $2.20B | -1.8% |
| Diluted EPS | $1.05 | $1.62 | $1.08 | |
| Operating cash flow | $4.18B | $3.39B | $6.31B | -33.8% |
| Capital expenditures | -$344.00M | -$305.00M | -$320.00M | |
| Free cash flow | $3.84B | $3.09B | $5.99B | -36.0% |
| Dividend per share | $0.63 | $0.63 | $0.62 |
| Q3 FY26 | Q3 FY25 | Year over year | |
|---|---|---|---|
| Eliquis Worldwide Revenue | $4.69B | $3.75B | +25.2% |
| Opdivo Worldwide Revenue | $2.37B | $2.53B | -6.2% |
| Breyanzi Revenue | $526.00M | $359.00M | +46.5% |
| Zeposia Revenue | $168.00M | $161.00M | +4.3% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Bristol Myers Squibb (BMY) Q3 FY26 earnings: results and KPIs”, stockatlas.com/companies/BMY/earnings/2026-q3/, data as of 3 November 2026. Links to this page are welcome.
